Blog

  • Android Auto gets a redesigned Spotify app [Gallery]

    Android Auto gets a redesigned Spotify app [Gallery]

    Rolling out with the latest update, Spotify is getting a redesign on Android Auto and also adding support for “Jam” on the car’s display.

    Announced back at Google I/O 2025 earlier this year, Spotify is now taking advantage of Android Auto’s newfound flexibility in media apps. An update available now brings additional functionality to Spotify’s Android Auto app, most notably including support for “Jam.”

    The new Spotify app includes a handful of key changes. There’s now a more prominent “Downloaded” section in your Library, allowing you to only use music that’s available offline. That might be handy when driving on rural roads without stable signal. You’ll also now see an indicator on downloaded tracks while browsing albums or playlists.

    There are also some minor UI changes throughout the app, as well as a new floating Search shortcut that opens a dedicated search page for Spotify. Previously, Google Assistant was the sole was to search for music and it would just start playing. Now, you can search for albums or tracks and see results in the app.

    Advertisement – scroll for more content

    Finally, the big addition is Spotify Jam. This feature, found on the “Now Playing” page, pulls up a QR code which other users can scan to start collaborating on the current music queue. The driver is the host, with guests able to add music which is then played through the car, which seems like a really useful feature for road trips. Once a guest has been added, the app will easily allow them to be removed by the driver.

    This change appears to be attached to Spotify 9.0.58.596 for Android, available now via the Play Store.

    Other media apps are likely to start getting similar updates in the months to come, with Google having confirmed Amazon Music and YouTube Music will both leverage the added flexibility in time.

    More on Android Auto:

    Follow Ben: Twitter/X, Threads, Bluesky, and Instagram

    FTC: We use income earning auto affiliate links. More.


    Continue Reading

  • SUSE’s Agama Installer Switches From X.Org To Wayland For Installation GUI

    SUSE’s Agama Installer Switches From X.Org To Wayland For Installation GUI

    SUSE developers working on their new operating system installer “Agama” have been making steady progress and on Friday debuted Agama 16. With Agama 16 they have moved from X.Org to Wayland for powering their installer UI along with a number of other changes.

    The Agama 16 operating system installer has introduced better matching for storage devices, installation status reporting via IPMI for Linux servers, initial support for using existing MD RAID arrays from the Agama web interface UI, a more friendly experience for remote installations, checking the strength of typed passwords, and other enhancements.

    Agama 16

    SUSE also decided that it’s time to switch from using the X.Org Server to Wayland as the display server for running their Firefox-based web UI for the installer on graphical installations. Switching to Wayland did increase the install image size compared to their former images using X11 but they are going to be working on improvements there along with restoring some now-missing keyboard shortcut support.

    SUSE continues working on the Agama operating system installer so that it will be ready for use with the upcoming openSUSE Leap 16.0 and SUSE Linux Enterprise 16.0 operating system releases. More details on the Agama 16 changes via the Agama project blog.

    Continue Reading

  • Julian McMahon, ‘Nip/Tuck’ and ‘Fantastic Four’ Actor, Dead at 56

    Julian McMahon, ‘Nip/Tuck’ and ‘Fantastic Four’ Actor, Dead at 56

    Julian McMahon, the actor best known for starring in the medical drama Nip/Tuck and portraying Doctor Doom in the Fantastic Four films, has died at the age of 56.

    The Australian-born actor’s wife Kelly confirmed McMahon’s death in a statement to Deadline, adding that he died July 2 in Clearwater, Florida following a private battle with cancer. McMahon’s rep also confirmed the death to the Hollywood Reporter.

    “With an open heart, I wish to share with the world that my beloved husband, Julian McMahon, died peacefully this week after a valiant effort to overcome cancer,” Kelly said in the statement.

    “Julian loved life. He loved his family. He loved his friends. He loved his work, and he loved his fans. His deepest wish was to bring joy into as many lives as possible,” she continued. “We ask for support during this time to allow our family to grieve in privacy. And we wish for all of those to whom Julian brought joy, to continue to find joy in life. We are grateful for the memories.”

    McMahon, the son of former Australian prime minister William McMahon, was first a television star in his native country, appearing in the popular soap operas The Power, the Passion and Home and Away before making the jump to Hollywood in the mid-Nineties.

    In 1996, McMahon was the lead role in the NBC crime drama Profiler and part of the main cast of the supernatural series Charmed before landing a co-starring role on Nip/Tuck in 2003. McMahon played plastic surgeon Christian Troy on that hit Ryan Murphy-created FX show, which ran for six seasons and 100 episodes.

    During his Nip/Tuck run, McMahon was cast as the Marvel villain Victor Von Doom, a.k.a. Doctor Doom, in 2005’s Fantastic Four and its 2007 sequel Fantastic Four: Rise of the Silver Surfer.

    Trending Stories

    Ioan Gruffudd, who played Reed “Mr. Fantastic” Richards in those Fantastic Four films, paid tribute to McMahon on social media, “Even though we played each other’s nemeses, there was always so much lightness and laughter working together,” he wrote. “Every encounter with him was a joy. It was an honor to be Dr. Richards to his Dr. Doom. My heart goes out to his wife and family. God speed Julian.”

    McMahon’s recent roles include playing Special Agent Jess LaCroix across three series in CBS’ FBI franchise, co-starring alongside Nicolas Cage in 2024’s The Surfer, and — in a role that recalled his father’s position — playing an Australian prime minister in the Netflix White House murder-mystery The Residence.


    Continue Reading

  • Frozen light switches: How Arctic microbes could revolutionize neuroscience

    Frozen light switches: How Arctic microbes could revolutionize neuroscience

    Imagine the magnificent glaciers of Greenland, the eternal snow of the Tibetan high mountains, and the permanently ice-cold groundwater in Finland. As cold and beautiful these are, for the structural biologist Kirill Kovalev, they are more importantly home to unusual molecules that could control brain cells’ activity.

    Kovalev, EIPOD Postdoctoral Fellow at EMBL Hamburg’s Schneider Group and EMBL-EBI’s Bateman Group, is a physicist passionate about solving biological problems. He is particularly hooked by rhodopsins, a group of colorful proteins that enable aquatic microorganisms to harness sunlight for energy.

    “In my work, I search for unusual rhodopsins and try to understand what they do,” said Kovalev. “Such molecules could have undiscovered functions that we could benefit from.”

    Some rhodopsins have already been modified to serve as light-operated switches for electrical activity in cells. This technique, called optogenetics, is used by neuroscientists to selectively control neuronal activity during experiments. Rhodopsins with other abilities, such as enzymatic activity, could be used to control chemical reactions with light, for example.

    Having studied rhodopsins for years, Kovalev thought he knew them inside out – until he discovered a new, obscure group of rhodopsins that were unlike anything he had seen before.

    As it often happens in science, it started serendipitously. While browsing online protein databases, Kovalev spotted an unusual feature common to microbial rhodopsins found exclusively in very cold environments, such as glaciers and high mountains. “That’s weird,” he thought. After all, rhodopsins are something you typically find in seas and lakes.

    These cold-climate rhodopsins were almost identical to each other, even though they evolved thousands of kilometres apart. This couldn’t be a coincidence. They must be essential for surviving in the cold, concluded Kovalev, and to acknowledge this, he named them ‘cryorhodopsins’.

    Rhodopsins out of the blue

    Kovalev wanted to know more: what these rhodopsins look like, how they work, and, in particular, what color they are.

    Color is the key feature of each rhodopsin. Most are pink-orange – they reflect pink and orange light, and absorb green and blue light, which activates them. Scientists strive to create a palette of different colored rhodopsins, so they could control neuronal activity with more precision. Blue rhodopsins have been especially sought-after because they are activated by red light, which penetrates tissues more deeply and non-invasively.

    To Kovalev’s amazement, the cryorhodopsins he examined in the lab revealed an unexpected diversity of colors, and, most importantly, some were blue.

    The color of each rhodopsin is determined by its molecular structure, which dictates the wavelengths of light it absorbs and reflects. Any changes in this structure can alter the color.

    “I can actually tell what’s going on with cryorhodopsin simply by looking at its color,” laughed Kovalev.

    Applying advanced structural biology techniques, he figured out that the secret to the blue color is the same rare structural feature that he originally spotted in the protein databases.

    “Now that we understand what makes them blue, we can design synthetic blue rhodopsins tailored to different applications,” said Kovalev.

    Next, Kovalev’s collaborators examined cryorhodopsins in cultured brain cells. When cells expressing cryorhodopsins were exposed to UV light, it induced electric currents inside them. Interestingly, if the researchers illuminated the cells right afterwards with green light, the cells became more excitable, whereas if they used UV/red light instead, it reduced the cells’ excitability.

    “New optogenetic tools to efficiently switch the cell’s electric activity both ‘on’ and ‘off’ would be incredibly useful in research, biotechnology and medicine,” said Tobias Moser, Group Leader at the University Medical Center Göttingen who participated in the study. “For example, in my group, we develop new optical cochlear implants for patients that can optogenetically restore hearing in patients. Developing the utility of such a multi-purpose rhodopsin for future applications is an important task for the next studies.”

    “Our cryorhodopsins aren’t ready to be used as tools yet, but they’re an excellent prototype. They have all the key features that, based on our findings, could be engineered to become more effective for optogenetics,” said Kovalev.

    Evolution’s UV light protector

    When exposed to sunlight even on a rainy winter day in Hamburg, cryorhodopsins can sense UV light, as shown using advanced spectroscopy by Kovalev’s collaborators from Goethe University Frankfurt led by Josef Wachtveitl. Wachtveitl’s team showed that cryorhodopsins are in fact the slowest among all rhodopsins in their response to light. This made the scientists suspect that those cryorhodopsins might act like photosensors letting the microbes ‘see’ UV light – a property unheard of among other cryorhodopsins.

    “Can they really do that?” Kovalev kept asking himself. A typical sensor protein teams up with a messenger molecule that passes information from the cell membrane to the cell’s inside.

    Kovalev grew more convinced, when together with his collaborators from Alicante, Spain, and his EIPOD co-supervisor, Alex Bateman from EMBL-EBI, they noticed that the cryorhodopsin gene is always accompanied by a gene encoding a tiny protein of unknown function – likely inherited together, and possibly functionally linked.

    Kovalev wondered if this might be the missing messenger. Using the AI tool AlphaFold, the team were able to show that five copies of the small protein would form a ring and interact with the cryorhodopsin. According to their predictions, the small protein sits poised against the cryorhodopsin inside the cell. They believe that when cryorhodopsin detects UV light, the small protein could depart to carry this information into the cell.

    “It was fascinating to uncover a new mechanism via which the light-sensitive signal from cryorhodopsins could be passed on to other parts of the cell. It is always a thrill to learn what the functions are for uncharacterised proteins. In fact, we find these proteins also in organisms that do not contain cryorhodopsin, perhaps hinting at a much wider range of jobs for these proteins.”

    Why cryorhodopsins evolved their astonishing dual function – and why only in cold environments – remains a mystery.

    “We suspect that cryorhodopsins evolved their unique features not because of the cold, but rather to let microbes sense UV light, which can be harmful to them,” said Kovalev. “In cold environments, such as the top of a mountain, bacteria face intense UV radiation. Cryorhodopsins might help them sense it, so they could protect themselves. This hypothesis aligns well with our findings.”

    “Discovering extraordinary molecules like these wouldn’t be possible without scientific expeditions to often remote locations, to study the adaptations of the organisms living there,” added Kovalev. “We can learn so much from that!”

    Unique approach to unique molecules

    To reveal the fascinating biology of cryorhodopsins, Kovalev and his collaborators had to overcome several technical challenges.

    One was that cryorhodopsins are nearly identical in structure, and even a slight change in the position of a single atom can result in different properties. Studying molecules at this level of detail requires going beyond standard experimental methods. Kovalev applied a 4D structural biology approach, combining X-ray crystallography at EMBL Hamburg beamline P14 and cryo-electron microscopy (cryo-EM) in the group of Albert Guskov in Groningen, Netherlands, with protein activation by light.

    “I actually chose to do my postdoc at EMBL Hamburg, because of the unique beamline setup that made my project possible,” said Kovalev. “The whole P14 beamline team worked together to tailor the setup to my experiments – I’m very grateful for their help.”

    Another challenge was that cryorhodopsins are extremely sensitive to light. For this reason, Kovalev’s collaborators had to learn to work with the samples in almost complete darkness.

    Continue Reading

  • Tennis coach finds out he has brain cancer after one beer

    Tennis coach finds out he has brain cancer after one beer

    Simon Bowler, 50, from the U.K., was known as an active, healthy man with no underlying conditions. He often enjoyed a beer with friends without any problems. But in October 2023, a single beer left him feeling faint and unsteady, People reported.

    Shortly after, a lump appeared on his neck. Doctors initially thought it was just a benign cyst. But as other alarming symptoms emerged, including blurred vision at night and abnormal hair growth on his head, Simon became worried.

    Further tests, including an ultrasound and biopsy, revealed the truth: the lump was melanoma, the most dangerous type of skin cancer.

    In February 2024, Simon underwent surgery to remove the tumor and began a year-long immunotherapy course to stop the cancer from returning. However, later that year, it had spread to his brain. His blurred vision and nighttime concentration problems returned, requiring radiation and more immunotherapy.

    Simon is currently pausing treatment due to complications while his medical team decides the next steps, People reported.

    Statistics show only half of patients with melanoma that has spread to the brain survive beyond five years.

    Despite his illness, Simon is determined to make a difference. In May 2025, he launched a GoFundMe campaign, raising nearly £7,000 (US$9,545) to start a tennis accessories business. He plans to donate part of the profits to charities including Macmillan, the NHS and mental health support funds.

    “I’ve been stripped of a lot of my identity, but I haven’t lost my will to keep going… I just want to get back to helping people, mentoring young players, and showing them what resilience looks like,” he said, the Daily Mail reported.

    Melanoma is caused by damage from UV and UVB rays from sunlight or tanning beds. Cases are rising among younger people. Doctors warn that melanoma can appear anywhere on the body, including the scalp, under fingernails, palms, soles, even inside the mouth.

    Experts recommend using high-SPF sunscreen, applying it 30 minutes before going outside, avoiding harsh midday sun and keeping children well protected.


    Continue Reading

  • Google Messages is working on more Material 3 Expressive elements

    Google Messages is working on more Material 3 Expressive elements

    The rollout of Android 16 happened sooner than we expected. However, the highly anticipated Material 3 Expressive design language won’t be available until the Android 16 QPR1 update later this year. In the meantime, we’ve seen multiple Google apps, such as Google Messages, introduce Material 3 Expressive elements into the app. The messaging app is now working on yet another change in line with the updated design philosophy.

    Related

    Material 3 Expressive brings what I love about Android into the modern day

    A UI redesign for the users

    An APK teardown of the latest Google Messages beta (version 20250701_01_RC00) by Android Authority has revealed work on a design refresh for the contact profile/chat info page. This page can be accessed by tapping the contact’s name at the top of a 1-1 conversation or from the list of chats by tapping the contact’s profile image, followed by the “i” icon.

    Current vs upcoming (via Android Authority)

    This redesign focuses on enlarging the four key buttons on the contact profile page: Call, Video, Contact info, and Search. Compared to the current set of buttons, the upcoming version features significantly larger, oval-shaped buttons. These changes align with the Material 3 Expressive updates we’ve seen across multiple Google apps so far.

    The updated visual elements should be available imminently

    In addition to their larger size, Google is giving these four buttons more flair. A video uploaded by Android Authority shows how the buttons expand momentarily when the user interacts with them, which is a nice touch. It’s worth pointing out that this feature was manually activated, which means that simply sideloading the Google Messages beta APK on your Android smartphone won’t suffice.

    There are no specifics available on the wider rollout of this contact page redesign, which isn’t surprising given that it is only accessible through the beta version. However, with Material 3 Expressive being a big area of focus for Google in the coming months, we’d be surprised if these changes didn’t reach the stable version of Google Messages imminently.

    Similar to Google Messages, we’ve recently seen apps like Google Wallet gaining some Material 3 Expressive changes. Meanwhile, email client Gmail is also prepping an updated look in line with Android’s updated design language.

    Continue Reading

  • Top 5 Infectious Disease News Stories Week of June 28-July 5

    Top 5 Infectious Disease News Stories Week of June 28-July 5

    Why Fecal Transplants Sometimes Fail: Function, Not Just Colonization, May Hold the Key

    A recent Clemson University study reveals that fecal microbiota transplantation (FMT) may fail not due to poor colonization, but because transplanted microbes often don’t function properly in the recipient’s gut. Led by Anna Seekatz, PhD, and PhD candidate Sophie Millard, the research showed that even when human microbes successfully colonized mouse guts, they didn’t produce the necessary metabolites to fight C difficile infection. The study underscores that compatibility between donor microbes and the host’s gut environment—including immune responses, nutrient availability, and existing microbiota—is critical. This highlights the need for personalized, function-focused microbiome therapies rather than one-size-fits-all approaches.

    Moderna’s mRNA-1010 Shows Efficacy in Phase 3 Seasonal Flu Vaccine Trial

    Moderna’s mRNA-1010 seasonal flu vaccine candidate has shown promising results in a phase 3 trial, demonstrating 26.6% higher relative efficacy compared to a standard-dose flu vaccine in adults aged 50 and older. The study, which included over 40,000 participants across 11 countries, showed strong protection against multiple influenza strains, including A/H1N1, A/H3N2, and B/Victoria. Participants aged 65+ saw a 27.4% increase in efficacy. The vaccine was well tolerated, with mostly mild side effects and no major safety concerns. These findings highlight the potential of mRNA technology to improve flu vaccination, especially for older adults, and support ongoing efforts toward regulatory approval.

    West Nile Virus Dominated Arboviral Cases in 2023, as CDC Reports First US Infection With Lineage 3 Strain

    In 2023, West Nile virus (WNV) accounted for 95% of the 2,770 reported arboviral cases in the US, resulting in over 2,000 hospitalizations and 208 deaths, according to a CDC report. Notably, the first US human case of WNV lineage 3—a strain previously found only in European mosquitoes—was identified, raising concerns about surveillance gaps. The patient was coinfected with both lineage 1 and 3, highlighting the need for improved diagnostic tools and expanded surveillance. The CDC also reported increased cases of Powassan virus and La Crosse virus, underscoring the growing diversity of arboviral threats. Experts emphasize the importance of mosquito control, clinician awareness, donor screening, and enhanced testing to better detect and respond to emerging arboviral diseases.

    New Advances in Chronic Hepatitis B: Non-Invasive Fibrosis Algorithm and Immunoadsorption Therapy

    Two recent studies published in BMC Gastroenterology highlight major advances in chronic hepatitis B (CHB) care. The first validates a non-invasive fibrosis staging algorithm using five routine lab variables—platelet count, ALT, AST, GGT, and age—to accurately identify both advanced fibrosis and minimal liver damage without the need for biopsy, making it especially valuable in primary care and low-resource settings. The second study introduces a novel immunoadsorption therapy using anti-HBsAg antibody-coated beads, which significantly reduced HBsAg and HBV DNA levels in a preclinical rabbit model. This approach shows potential as an adjunct to current therapies aiming for a functional cure, though human trials are still needed.

    FDA Food Recalls Announced in June 2025 Due to Potential Contamination Risks

    In June 2025, the FDA announced multiple nationwide food recalls due to potential contamination with harmful bacteria, including Salmonella, Listeria monocytogenes, Clostridium botulinum, and Bacillus cereus. Major recalls included millions of eggs from August Egg Company and cucumbers from several suppliers due to Salmonella risk, as well as shrimp, enoki mushrooms, and cheese curds potentially contaminated with Listeria. Additional recalls involved salted smoked herring contaminated with C botulinum and children’s cough syrup tainted with B cereus. While no related illnesses were reported, the incidents underscore the ongoing need for robust food safety surveillance and consumer awareness to prevent foodborne illnesses.

    Continue Reading

  • Key FDA approvals in pediatric health: First half of 2025

    Key FDA approvals in pediatric health: First half of 2025

    Key FDA approvals in pediatric health: First half of 2025 | Image Credit: © Postmodern Studio – stock.adobe.com.

    The first half of 2025 has seen a surge of FDA approvals that expand treatment options and improve access to care for patients across multiple pediatric and adolescent health conditions.

    From novel vaccines and needle-free emergency treatments to groundbreaking therapies for rare diseases, HIV prevention, and autoimmune disorders, these approvals reflect critical strides in both innovation and accessibility. Many of the newly authorized therapies offer more convenient dosing, at-home administration, or first-in-class mechanisms, addressing long-standing clinical gaps and supporting personalized care.

    In this midyear roundup, Contemporary Pediatrics highlights the most impactful FDA decisions from January through June 2025 that are shaping the future of care for infants, children, and teens.

    Click on each title below to read more.

    1. FDA approves GSK’s meningococcal ABCWY vaccine

    On February 14, 2025, the FDA approved the meningococcal ABCWY (MenABCWY, Penmenvy; GSK) vaccine for individuals aged 10 to 25 years, offering protection against the five major serogroups (A, B, C, W, Y) of Neisseria meningitidis, which cause invasive meningococcal disease (IMD).

    The vaccine combines components of the meningococcal group B vaccine (Bexsero) and the ACYW conjugate vaccine (Menveo). Approval was based on a phase 3 trial (NCT04502693) involving 3,650 participants across seven countries, demonstrating strong immunogenicity, non-inferiority to existing vaccines, and a well-tolerated safety profile. MenB accounts for over half of IMD cases in Sadolescents and young adults, yet vaccination rates remain low.

    2. FDA approves neffy 1 mg for anaphylaxis in children aged 4 years and older

    The FDA approved epinephrine nasal spray (neffy; ARS Pharmaceuticals) 1 mg on March 5, 2025, for children aged 4 years and older weighing 33 to 66 lbs, making it the first needle-free epinephrine treatment for younger pediatric patients. This expands its indication beyond the original August 2024 approval for patients weighing at least 66 lbs.

    Expected to launch in the United States by May 2025, neffy offers a user-friendly, temperature-stable alternative to traditional epinephrine auto-injectors, addressing fears of needle-based administration that often delay treatment. Approval was based on pharmacokinetic and pharmacodynamic data showing comparable efficacy to injectable epinephrine.

    3. FDA approves diazoxide choline extended-release tablets for hyperphagia in Prader-Willi syndrome

    The FDA approved diazoxide choline extended-release tablets (VYKAT XR; Soleno Therapeutics) on March 26, 2025, for treating hyperphagia in individuals aged 4 years and older with Prader-Willi syndrome (PWS). Granted priority review, breakthrough therapy, fast track, and orphan drug designations, VYKAT XR is the first approved treatment specifically addressing hyperphagia, a hallmark symptom of PWS.

    In phase 3 trials, the treatment significantly improved hyperphagia, aggressive behaviors, fat mass, and metabolic parameters, with patients showing greater reductions in hyperphagia scores at 26 and 52 weeks compared to natural history data (P < 0.001). PWS, which affects approximately 1 in 15,000 live births, is associated with persistent hunger, cognitive disabilities, and metabolic challenges. Advocacy groups and researchers hailed the approval as a critical advancement for the PWS community.

    4. FDA approves clesrovimab to protect infants during first RSV season

    On June 9, 2025, the FDA approved Merck’s clesrovimab (Enflonsia), an extended half-life monoclonal antibody, to protect infants from respiratory syncytial virus (RSV) during their first RSV season. The approval was supported by positive results from the phase 2b/3 CLEVER and phase 3 SMART trials, which demonstrated that a single dose of clesrovimab significantly reduced RSV-related infections and hospitalizations in both healthy and high-risk infants. In the CLEVER trial, clesrovimab reduced medically attended lower respiratory infections by 60.5%, RSV-related hospitalizations by 84.3%, and severe RSV cases by over 90% through 5 months post-dose (P < 0.001 for all). Unlike other monoclonal antibodies, clesrovimab targets site 4 of the RSV fusion protein, neutralizing more than 96% of RSV A and B strains. The therapy, given as a fixed intramuscular dose, offers direct, rapid, and durable protection throughout a typical RSV season.

    5. FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis

    On June 15, 2025, the FDA approved a new presentation of ustekinumab-stba (Steqeyma; Celltrion), a biosimilar to ustekinumab (Stelara), in a 45mg/0.5mL single-dose vial for subcutaneous injection. The new dosage form is indicated for patients aged 6 to 17 years weighing under 60 kg with plaque psoriasis or psoriatic arthritis. With this approval, ustekinumab-stba matched all dosing forms of the reference product. The decision was supported by phase 3 data showing clinical similarity to the reference biologic, with no meaningful differences in safety or efficacy.

    6. FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older

    On June 17, 2025, FDA approved CSL’s garadacimab-gxii (Andembry), a first-in-class monoclonal antibody targeting factor XIIa, to prevent hereditary angioedema (HAE) attacks in patients aged 12 years and older. Approval was based on the phase 3 VANGUARD trial, where once-monthly garadacimab-gxii reduced mean HAE attack rates by 86.5% and median attack rates by over 99% compared to placebo (P < 0.001). An open-label extension study also showed sustained efficacy and a favorable long-term safety profile. Experts highlighted its novel mechanism and convenient dosing as key advances for HAE management. Meanwhile, FDA review of another HAE therapy, sebetralstat, has been delayed due to resource constraints, though no concerns about its safety or efficacy were raised.

    7. FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

    On June 18, 2025, the FDA approved lenacapavir (Yeztugo; Gilead Sciences), the first and only twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in individuals aged 12 and older weighing at least 35 kg. Approval was based on results from the phase 3 PURPOSE 1 and PURPOSE 2 trials, in which lenacapavir showed no HIV infections among cisgender women in sub-Saharan Africa (PURPOSE 1) and just 2 infections among 2179 participants in a diverse population including cisgender men and gender-diverse people (PURPOSE 2), achieving over 99.9% effectiveness in both trials. The treatment demonstrated superiority over once-daily oral Truvada (F/TDF), offering a long-acting option for people who prefer or require less frequent dosing. Experts hailed the approval as a major step forward in HIV prevention, potentially improving adherence and reducing stigma associated with daily PrEP.

    8. FDA approves at-home belimumab autoinjector for children with lupus nephritis

    On June 24, 2025, the FDA approved a 200 mg/mL autoinjector formulation of belimumab (Benlysta; GSK) for at-home use in children aged 5 years and older with active lupus nephritis (LN), making it the first subcutaneous, self-administered biologic treatment for pediatric LN. Originally approved for adult SLE in 2011 and expanded to pediatric indications in later years, this new formulation offers a convenient alternative to intravenous infusions, potentially reducing clinic visits and easing treatment burdens for families. The decision was based on belimumab’s established safety and efficacy profile. Experts noted that pediatric lupus is often more severe than adult-onset disease, making flexible treatment options critical. The autoinjector is now available for eligible patients and can be administered by a health care provider or trained caregiver at home.

    Continue Reading

  • Ollie Bearman hit with 10-place grid drop for British Grand Prix after red flag infringement in final practice

    Ollie Bearman hit with 10-place grid drop for British Grand Prix after red flag infringement in final practice

    Ollie Bearman has been handed a 10-place grid penalty for the British Grand Prix following a red flag infringement during the weekend’s third and final practice hour.

    The session had already proven eventful for Bearman, the Haas driver earlier sparking a red flag after losing a piece of bodywork from his car out on track which resulted in the marshals having to retrieve the part.

    But there was worse to come for the Briton when a second red flag was thrown in the latter stages owing to Kick Sauber’s Gabriel Bortoleto spinning off and becoming beached in the gravel.

    As he headed into the pit lane, Bearman had a spin of his own and hit the barriers, losing the front wing from his VF-25 in the process.

    With the incident happening under red flag conditions, it was subsequently investigated by the stewards who opted to hand the 20-year-old a grid drop of 10 places for Sunday’s race.

    A document released following the stewards’ hearing reads: “Car 87 had slowed down for the red flag and as he was approaching Turn 15 accelerated significantly to race pace and entered the pit entry road at 260kph. He lost control of the car in the pit entry road and crashed into the barriers.

    “Art. 37.6 (a) of the Formula One Sporting Regulations and Art. 2.5.4.1(b) of Appendix H of the International Sporting Code require that when a red flag is shown ‘all cars must immediately reduce speed and proceed slowly back to the pit lane’.

    “It is beyond doubt that the driver of Car 87 did not proceed slowly back to the pit lane when he accelerated to simulate entering into the pit entry road under race conditions.

    “In fact, we looked at a previous in-lap under normal racing conditions and found that he was faster in this lap, under a red flag.

    “To make matters worse, he lost control of the car and crashed into the barriers while at speed. The driver informed us that he misjudged the fact that his brakes were not warm because the lap was done slowly, due to the red flag.

    “While this may have been a factor contributing to the crash, we did not consider it to be a mitigating factor.”

    As well as the grid penalty, Bearman has also received four penalty points, bringing the total on his licence up to eight.

    The British driver is competing in his first home Grand Prix as an F1 driver, with last year’s event at Silverstone being where the youngster’s deal to race for Haas in 2025 was announced.

    Continue Reading

  • PPP will remain key ally despite PML-N securing simple majority, says Dar

    PPP will remain key ally despite PML-N securing simple majority, says Dar

    President Asif Ali Zardari receives PM Shebaz Sharif for a meeting. — X/@MediaCellPPP
    • Ishaq Dar says PPP is and will remain coalition partner.
    • Adds forming govt won’t be possible without PPP.
    • Ruling PML-N got simple majority after getting reserved seats.

    Deputy Prime Minister and Foreign Minister Senator Ishaq Dar said on Saturday that the Pakistan Peoples Party (PPP) would remain a key ally of the Pakistan Muslim League-Nawaz (PML-N) despite the latter securing a simple majority in the National Assembly as a result of the reserved seats ruling.

    “PPP is and will remain our coalition partner,” said the deputy prime minister, recalling that without the PPP’s support, it would not have been possible to form a government following the 2024 general elections.

    Talking to journalists at Data Darbar shrine in Lahore, Dar said that the Bilawal Bhutto Zardari-led party stood by the government during difficult times and the Nawaz Sharif-led party would not abandon it in the times of stability.

    Responding to the reports that PML-N President Nawaz Sharif wanted to meet his chief political rival PTI founder Imran Khan in Adiala jail, Dar dismissed the claims as “wish list”.

    “These are all speculations. It must be someone’s wish list, as we don’t need to meet anyone. The law will take its own course. Such sponsored news is spread deliberately,” he added.

    However, the deputy prime minister said the ruling party was willing to work with all political parties, whether they are part of the government or the opposition.

    To a question, he replied that the coalition partner has not demanded any ministerial portfolios from the PML-N.

    His statement came after the Election Commission of Pakistan’s notification of reserved seats handed the ruling alliance a two-thirds majority in the lower house, as its strength rose from 218 to 235 members.

    The ECP notification came in line with the top court’s Constitutional Bench ruled that the Pakistan Tehreek-e-Insaf (PTI) was not entitled to seats reserved for women and minorities in the national and provincial assemblies, providing a lion’s share of the reserved seats to the ruling coalition.

    Earlier this week, PML-N senior leader and Defence Minister Khawaja Asif said it is entirely up to the PPP whether to join the current government or not.

    Speaking on Geo News programme “Capital Talk”, he described the previous PDM government’s past working relationship with PPP as “a good experience”.

    In a separate statement, Asif told Geo News that cooperation between the two major political parties could be fruitful for advancing the country’s national agenda.

    “I have been in politics for a considerable amount of time. The chances have increased substantially that if there’s an arrangement between both parties in which we can work for our national agenda, then it would be something good, and I would appreciate that,” he added.

    While noting that he could not provide a roadmap or confirm the details of any current negotiations, the senior PML-N leader said his comments were based on political experience rather than insider knowledge.


    Continue Reading